In the Middle East, various pay-to-prescribe schemes were used to induce healthcare providers to increase their prescriptions of Sanofi products. Charles Cain, FCPA unit chief at US SEC ...
5d
Hosted on MSNNovavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes RipplesNovavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved ... approval of Merilog to Sanofi (SNY)-Aventis U.S ...
Products that do not qualify for NAS status are considered to fall under the existing period of exclusivity of the previously authorised product, and for alglucosidase alfa. Sanofi said it would ...
6d
GlobalData on MSNSanofi’s Sarclisa combo approved in Japan for newly diagnosed MMSanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...
Sanofi's Sarclisa (isatuximab ... recently gained approval from China’s National Medical Products Administration, in particular for the Sarclisa-VRd combo for treating NDMM individuals who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results